nbc news semaglutide In the original clinical trials looking at (the GLP-1 in Novo Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the weight after States cracking down on compounding

FDA says cost, convenience, and supply preference do not create a 503B clinical need. Patients should not treat compounded GLP-1 products as FDA-approved generics

Aoyama, Shinya, et al

Trials find that those who use semaglutide drop more body weight compared to those who take a placebo

PlexusDx connects young adults with licensed practitioners who assess individual readiness and create personalized treatment protocols

Buyers should confirm import, labeling, distribution, and end-use requirements in their own market, using their own regulatory resources or advisors and should treat an investigational compound with particular care